Contract manufacturing set for major growth spurt

Contract manufacturing is set to more than double by 2021, and grow to $64.07 billion by 2016. Manufacturing of finished drugs will grow the most, according to a new report from Visiongain. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.